



ARTICLE

Epidemiology

Characteristics of The Cancer Genome Atlas cases relative to U.S. general population cancer cases

Xiaoyan Wang¹, Joseph T. Steensma¹, Matthew H. Bailey^{2,3}, Qianxi Feng¹, Hannah Padda¹ and Kimberly J. Johnson^{1,4}

BACKGROUND: Despite anecdotal reports of differences in clinical and demographic characteristics of The Cancer Genome Atlas (TCGA) relative to general population cancer cases, differences have not been systematically evaluated.

METHODS: Data from 11,160 cases with 33 cancer types were ascertained from TCGA data portal. Corresponding data from the Surveillance, Epidemiology, and End Results (SEER) 18 and North American Association of Central Cancer Registries databases were obtained. Differences in characteristics were compared using Student's *t*, Chi-square, and Fisher's exact tests. Differences in mean survival months were assessed using restricted mean survival time analysis and generalised linear model.

RESULTS: TCGA cases were 3.9 years (95% CI 1.7–6.2) younger on average than SEER cases, with a significantly younger mean age for 20/33 cancer types. Although most cancer types had a similar sex distribution, race and stage at diagnosis distributions were disproportional for 13/18 and 25/26 assessed cancer types, respectively. Using 12 months as an end point, the observed mean survival months were longer for 27 of 33 TCGA cancer types.

CONCLUSIONS: Differences exist in the characteristics of TCGA vs. general population cancer cases. Our study highlights population subgroups where increased sample collection is warranted to increase the applicability of cancer genomic research results to all individuals.

British Journal of Cancer (2018) 119:885–892; <https://doi.org/10.1038/s41416-018-0140-8>

INTRODUCTION

In recent years, progress in genome sequencing technologies and bioinformatics has provided enormous gains in understanding of the molecular aberrations associated with the development of various cancers. The emergence of publicly available cancer genomic datasets, including The Cancer Genome Atlas (TCGA), facilitates the comprehensive understanding of the molecular pathogenesis of cancer and is allowing for the development of new strategies to improve cancer diagnosis, therapy, and prevention. By analysing these publicly available genomic data, many novel disease-associated genes have been uncovered.^{1,2}

TCGA was formed in 2005 when the U.S. National Cancer and National Human Genome Research Institutes teamed together to support the launch of the project to comprehensively map various cancer genomic changes. To date, more than 11,000 individuals with 33 cancer types have been included in the cohort.^{3,4} These data have thus far contributed to >2000 studies of various cancers in PubMed.

The cohort composition for each cancer type is an important consideration since the results generated from these cases may be used to make inferences about the respective cancer type among the general population. Prior studies have shown that race, which is often used as a proxy for ancestry and social exposures, is related to the pathogenesis of cancer and different genetic backgrounds in common tumour types may influence clinical outcome and response to therapy.^{5–7} Evidence has shown that somatic mutation frequency differs by race in various cancer types,^{8–10} implying that

factors associated with race can impact the somatic mutation landscape. Other evidence also highlights the implications of sex and age dissimilarities in genetic susceptibility to cancer.^{11–13} For these reasons and because TCGA data was assembled mainly from an eligible convenience sample of cancer patients with strict sample selection criteria,¹⁴ it is important to understand similarities and differences in the characteristics of individuals who have contributed samples to TCGA relative to those of the general population of individuals diagnosed with cancer. A previous study of TCGA cases found that race/ethnicity disparities exist relative to the U.S. general population for ten cancer types examined comprising 5729 cases.¹⁵ Another study that analysed nine different cancer types in TCGA indicated a dissimilar age distribution in comparison with corresponding cases in the Surveillance, Epidemiology, and End Results (SEER) database.¹⁶ However, differences in demographic and clinical characteristics beyond race/ethnicity and age between members of the TCGA and the general U.S. population of cancer cases have not been systematically characterised.

In this study, we extend the results from previous studies by comparing demographic and clinical characteristics (age at diagnosis, sex, race, stage at diagnosis, and survival months) between TCGA cases with 33 cancer types and cases in two population-based databases: (1) the SEER 18 database that currently covers ~28% of the U.S. population,¹⁷ and (2) the U.S. combined registries of North American Association of Central

¹Brown School, Washington University in St. Louis, St. Louis MO, USA; ²Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis MO, USA; ³McDonnell Genome Institute, Washington University in St. Louis, St. Louis MO, USA and ⁴Siteman Cancer Center, Washington University in St. Louis, St. Louis MO, USA
Correspondence: Kimberly J. Johnson (kjohnson@wustl.edu)

Received: 24 January 2018 Revised: 15 May 2018 Accepted: 16 May 2018
Published online: 21 August 2018

Cancer Registries (NAACCR) that covers cancer registrations in all 50 states and the District of Columbia.¹⁸

METHODS

Population

Three separate data sources were used in this study: TCGA,¹⁹ the SEER 18 database,¹⁷ and the NAACCR public use dataset.²⁰ Data from individuals diagnosed with 33 cancer types were extracted from TCGA. No duplicate cases were found across various cancer types as determined by matching TCGA case IDs. Individuals with corresponding cancer types in SEER were identified using the third edition of the International Classification of Diseases for Oncology (ICD-O-3) by primary site and histology/behavior (Supplementary Table 1). To compare TCGA cases to a contemporary population of individuals diagnosed with cancer, only cases diagnosed with a primary malignancy from 2010 to 2013 in SEER were included. Since SEER intentionally oversamples U.S. minority populations,²¹ we used data from NAACCR to compare race distributions. This public use dataset published in the annual Cancer in North American (CiNA) Volumes covers cancer registrations in all 50 states and the District of Columbia, approaching 100% coverage of the U.S. population in the most recent time period.²² The most current five years (2009–2013) of data for U.S. and Canadian individuals diagnosed with cancer were available in this dataset. In this study, only U.S. cancer cases with available race data were included. The corresponding cancer types in NAACCR were defined using the cancer sites as denoted in Supplementary Table 1.

Variables

XML files from TCGA containing data on demographics, cancer variables, and follow-up status were downloaded from the National Cancer Institute Genomic Data Commons data portal¹⁹ on 22 December 2016. Python 3.6.0 was used to parse these files and extract the variables. Demographic data including diagnosis age, sex, and race were extracted from the “clin_shared:age_at_initial_pathologic_diagnosis”, “shared:gender”, “clin_shared:race” fields. Race was categorised as White, Black (African American), and Other (Asian, American Indian, or Alaska Native). Ethnicity was not included in this analysis due to the large proportion (24%) of cases with missing data for this field. Clinical information was extracted from the “shared_stage:clinical_stage”, “shared_stage:pathological_stage”, “shared_last_contact_days_to”, and “shared_death_days_to” fields. Stage was defined according to American Joint Committee on Cancer (AJCC) staging that includes categories I, II, III, and IV. Survival months were calculated using the “shared_last_contact_days_to” field for cases who were still alive and “shared_death_days_to” field for cases who were deceased during the follow-up period divided by days in a month (365.24/12).²³ Similarly, the demographic and clinical data of the 33 corresponding cancers were extracted from the SEER 18 database using SEER*Stat 8.3.4. Diagnosis age was based on the SEER variable “Age at diagnosis”. Race classifications were based on the “Race recode (W, B, AI, API)” variable and defined the same as above. Stage at diagnosis was defined using the “Derived AJCC Stage Group (7th edition 2010+)” variable. Survival months were defined using the “Survival months” variable. In NAACCR, the race categories were based on the “Race (Includes Hispanic)” variable and defined the same as for TCGA.

Statistical analysis

Stata version 14 was used for all analyses. Student’s *t*-test and Cohen’s *d*, a measure of effect size, were used to identify and quantify the statistical differences and effect sizes in diagnosis age. Cohen’s *d* is calculated as the difference between two means divided by the pooled standard deviation.²⁴ By convention, Cohen’s *d* ≥ 0.3 indicates at least a moderate effect size. Ordinary

least squares regression was used to estimate the overall mean difference in diagnosis age between TCGA and SEER cases with adjustment for cancer types. Chi-square and Fisher’s exact tests were used to identify proportion differences in sex, race, and stage. Additionally, for race and stage comparisons, adjusted residuals were used to determine categories with the largest difference relative to sample size. An adjusted residual ≥ 2.0 indicates that there was a significantly greater proportion of a particular race or stage category among TCGA cases than in the comparison population (i.e., NAACCR or SEER), while an adjusted residual ≤ −2.0 indicates a significantly lower proportion. We also quantified the mean all-cause survival months using restricted mean survival time (RMST) analysis²⁵ using 12 months as the end point to ensure that all TCGA cases that were included have the same window of observation. Since all TCGA cases were diagnosed prior to 2014, all had at least 12 months of follow-up time except for the cases who died during this period. For cases with over 12 survival months, the survival months were truncated at 12. The RMST approach is valid for any distribution of time to event.^{25–29} The between-group difference in mean survival with corresponding 95% confidence intervals (CIs) was estimated at 12-month horizon with adjustment for diagnosis age, sex, race, and stage if available for a specific cancer type, and a subsequent generalised linear model with robust standard errors. Statistical tests for all analyses were two-tailed tests and the critical value for alpha for all tests was 0.05.

RESULTS

Of 11,160 TCGA cases with 33 cancer types diagnosed between 1978 and 2013, 1097 cases were diagnosed with breast invasive carcinoma (BRCA) followed by glioblastoma multiforme (GBM, *n* = 596), ovarian serous cystadenocarcinoma (OV, *n* = 587), uterine corpus endometrial carcinoma (UCEC, *n* = 548), kidney renal clear cell carcinoma (KIRC, *n* = 537), head and neck squamous cell carcinoma (HNSC, *n* = 528), lung adenocarcinoma (LUAD, *n* = 522), and brain lower grade glioma (LGG, *n* = 515). Six cancers including adrenocortical carcinoma (ACC), cholangiocarcinoma (CHOL), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), mesothelioma (MESO), uterine carcinosarcoma (UCS), and uveal melanoma (UVM) had < 100 cases each. Among the corresponding 33 diagnoses in SEER, the number of cases ranged from 164 (UCS) to 203,828 (BRCA). In NAACCR, the number of cases ranged from 15,705 (MESO) to 1,085,443 (BRCA). Demographic and clinical characteristics of TCGA and SEER cases are shown in Table 1. The race distribution of TCGA and NAACCR cases is shown in Table 2.

Age at diagnosis

Overall, the mean diagnosis age of TCGA cases was 3.9 years younger (95% CI: 1.7–6.2, *P* < 0.001) than SEER cases after adjusting for cancer types (data not shown). The mean diagnosis age of TCGA cancer cases was not significantly different from that of SEER cases for a minority of cancers (CHOL, colon adenocarcinoma (COAD), KIRC, kidney renal papillary cell carcinoma (KIRP), pheochromocytoma and paraganglioma (PCPG), sarcoma (SARC), stomach adenocarcinoma (STAD), thymoma (THYM), and UVM). In contrast, for most cancer types (24/33), there were statistically significant differences in the mean diagnosis age. Among these, the majority (20/24) had a significantly younger mean diagnosis age with the exceptions of LGG, rectum adenocarcinoma (READ), UCEC, and UCS, TCGA cases that had statistically significant older mean diagnosis age than SEER cases (Fig. 1). The difference in the mean diagnosis age was especially pronounced for DLBC (8.4 ± 2.4 years younger in TCGA), oesophageal carcinoma (ESCA, 3.8 ± 0.9 years younger), kidney chromophobe (KICH, 7.4 ± 1.3 years younger), LGG (7.5 ± 0.9 years older), liver hepatocellular carcinoma (LIHC, 3.6 ± 0.7 years younger), MESO (8.4 ± 1.3 years younger), prostate adenocarcinoma (PRAD, 4.7 ± 0.4 years

Table 1. Demographic and clinical characteristics of TCGA and SEER cases

Cancer types	Age		Male		Stage		Restricted mean survival months							
							I		II		III		IV	
	TCGA ^a N (mean, SD)	SEER N (mean, SD)	TCGA N (%)	SEER N (%)	TCGA N (%)	SEER N (%)	TCGA N (%)	SEER N (%)	TCGA N (%)	SEER N (%)	TCGA N (%)	SEER N (%)	TCGA N (mean, SD)	SEER N (mean, SD)
All cancers	11,109 (59.1, 14.4)	1,027,049 (63.0, 13.9)	—	—	—	—	—	—	—	—	—	—	—	—
ACC	92 (47.2, 16.3)	349 (52.5, 20.0)	32 (34.8)	131 (37.5)	9 (10.0)	15 (4.4)	44 (48.9)	103 (30.5)	19 (21.1)	48 (14.2)	18 (20.0)	172 (50.9)	79 (11.7, 1.3)	337 (8.9, 4.3)
BLCA	412 (68.1, 10.6)	49,593 (70.1, 12.1)	304 (73.8)	37,796 (76.2)	2 (0.5)	10,796 (51.9)	131 (32.0)	5353 (25.7)	141 (34.4)	1644 (7.9)	136 (33.2)	3005 (14.5)	391 (11.1, 2.3)	20,621 (10.4, 3.3)
BRCA	1096 (58.4, 13.2)	203,828 (60.7, 13.6)	12 (1.1)	1,474 (0.7)	183 (17.1)	97,507 (49.5)	621 (57.9)	65,060 (33.0)	249 (23.1)	23,245 (11.8)	20 (1.9)	11,363 (5.8)	979 (11.9, 0.5)	195,859 (11.8, 1.5)
CEC	307 (48.3, 13.8)	11,454 (50.1, 14.7)	—	—	163 (54.3)	5343 (49.0)	70 (23.3)	1494 (13.7)	46 (15.3)	2471 (22.6)	21 (7.0)	1606 (14.7)	259 (11.6, 1.4)	10,799 (11.2, 2.5)
CHOL	45 (63.6, 12.2)	4743 (67.3, 13.2)	20 (44.4)	2363 (49.8)	20 (44.4)	569 (17.6)	11 (24.4)	541 (16.8)	4 (8.9)	270 (8.4)	10 (22.2)	1846 (57.2)	43 (10.6, 3.3)	3214 (7.0, 4.7)
COAD	459 (66.9, 13.1)	78,858 (66.7, 14.1)	243 (52.9)	38,938 (49.4)	76 (17.0)	17,127 (23.2)	178 (39.7)	20,294 (27.5)	129 (28.8)	19,987 (27.1)	65 (14.5)	16,464 (22.3)	268 (11.6, 1.7)	73,335 (10.5, 3.5)
DLBC	48 (55.3, 14.2)	20,129 (63.7, 16.7)	22 (45.8)	11,040 (54.9)	8 (19.1)	2937 (17.3)	17 (40.5)	3916 (23.1)	5 (11.9)	3497 (20.6)	12 (28.6)	6604 (39.0)	41 (11.9, 0.4)	16,804 (9.7, 4.1)
ESCA	185 (62.5, 11.9)	12,068 (66.3, 11.7)	158 (85.4)	9617 (79.7)	18 (11.1)	1934 (18.3)	79 (48.8)	1860 (17.6)	56 (34.6)	2927 (27.7)	9 (5.6)	3854 (36.4)	143 (10.8, 2.6)	10,429 (8.2, 4.4)
GBM	596 (57.8, 14.4)	9818 (62.1, 14.7)	366 (61.4)	5628 (57.3)	—	—	—	—	—	—	—	566 (9.1, 3.9)	9743 (7.7, 4.5)	
HNSC	527 (60.9, 11.9)	36,907 (62.5, 12.2)	386 (73.1)	27,933 (75.7)	27 (6.0)	7330 (22.4)	74 (16.3)	3924 (12.0)	82 (18.1)	5589 (17.1)	270 (59.6)	15,873 (48.5)	437 (11.1, 2.4)	32,482 (10.8, 2.9)
KICH	113 (51.2, 13.9)	2151 (58.6, 13.9)	62 (54.9)	1185 (55.1)	54 (47.8)	1380 (65.6)	33 (29.2)	377 (17.9)	19 (16.8)	303 (14.4)	7 (6.2)	45 (2.1)	110 (11.9, 1.1)	2076 (11.9, 0.9)
KIRC	537 (60.6, 12.2)	22,371 (60.3, 12.4)	346 (64.4)	13,855 (61.9)	269 (50.4)	13,769 (62.7)	57 (10.7)	1913 (8.7)	125 (23.4)	3722 (17.0)	83 (15.5)	2550 (11.6)	522 (11.4, 2.1)	21,768 (11.5, 2.1)
KIRP	288 (61.5, 12.1)	4576 (61.3, 11.9)	214 (73.5)	3406 (74.4)	173 (66.3)	3249 (73.7)	21 (8.1)	449 (10.2)	52 (19.9)	447 (10.1)	15 (5.8)	266 (6.0)	244 (11.8, 0.9)	4362 (11.5, 2.1)
LAML	200 (55.0, 16.1)	11,671 (60.3, 21.7)	109 (54.5)	6336 (54.3)	—	—	—	—	—	—	—	—	173 (9.6, 3.6)	11,491 (7.0, 5.0)
LGG	515 (42.9, 13.4)	952 (35.4, 20.6)	285 (55.3)	536 (56.3)	—	—	—	—	—	—	—	—	500 (11.7, 1.4)	943 (11.4, 2.3)
LIHC	376 (59.5, 13.5)	22,642 (63.1, 11.0)	255 (67.6)	17,529 (77.4)	175 (49.6)	7604 (40.3)	87 (24.7)	3774 (20.0)	86 (24.4)	3520 (18.7)	5 (1.4)	3953 (21.0)	320 (11.1, 2.7)	18,716 (7.9, 4.8)
LUAD	503 (65.3, 10.0)	69,483 (67.4, 11.5)	242 (46.4)	33,003 (47.5)	279 (54.3)	15,333 (22.8)	124 (24.1)	5027 (7.5)	85 (16.5)	10,599 (15.8)	26 (5.1)	36,182 (53.9)	444 (11.3, 1.9)	66,875 (8.3, 4.6)
LUSC	495 (67.3, 8.6)	31,355 (69.7, 10.1)	373 (74.0)	19,553 (62.4)	245 (49.0)	6069 (20.3)	163 (32.6)	3803 (12.7)	85 (17.0)	8815 (29.5)	7 (1.4)	11173 (37.4)	381 (10.8, 2.7)	29,771 (7.9, 4.6)
MESO	87 (63.0, 9.8)	2561 (71.4, 12.3)	71 (81.6)	1928 (75.3)	10 (11.5)	437 (21.7)	16 (18.4)	21 (11.0)	45 (51.7)	466 (23.1)	16 (18.4)	892 (44.3)	85 (10.2, 3.1)	2011 (7.5, 4.5)
OV	587 (59.7, 11.5)	5126 (62.7, 12.6)	—	—	6 (1.1)	456 (9.1)	30 (5.3)	400 (8.0)	446 (78.1)	2669 (53.2)	89 (15.6)	1495 (29.8)	543 (11.3, 2.5)	5003 (10.9, 3.0)
PAAH	185 (64.9, 11.1)	29,367 (67.2, 12.1)	102 (55.1)	15,141 (51.7)	21 (11.5)	2587 (9.3)	152 (83.5)	8036 (28.7)	4 (2.2)	2708 (9.7)	5 (2.8)	14,629 (52.3)	173 (10.3, 2.9)	27,851 (6.8, 4.7)
PCPG	179 (47.3, 15.1)	176 (50.2, 18.9)	78 (43.6)	91 (51.7)	—	—	—	—	—	—	—	—	175 (11.9, 1.0)	166 (11.3, 2.5)
PRAD	500 (61.0, 6.8)	195,005 (65.7, 9.1)	—	—	—	—	—	—	—	—	—	—	156 (12.0, 0.0)	186,537 (11.8, 1.1)
READ	170 (64.5, 11.9)	26,251 (61.5, 13.5)	92 (54.1)	15,357 (58.5)	33 (20.5)	7346 (32.7)	51 (31.7)	4705 (21.0)	52 (32.3)	6335 (28.2)	25 (15.5)	4065 (18.1)	80 (11.9, 0.2)	22,242 (11.1, 2.6)
SARC	261 (60.9, 14.7)	3256 (59.3, 20.4)	119 (45.6)	1734 (53.3)	—	—	—	—	—	—	—	—	252 (11.6, 1.7)	3158 (9.2, 4.4)
SKCM	462 (58.2, 15.7)	61,799 (59.9, 16.3)	290 (61.7)	34,964 (56.6)	91 (21.4)	43,082 (76.2)	140 (32.9)	6950 (12.3)	171 (40.2)	4321 (7.6)	23 (5.4)	2205 (3.9)	405 (11.8, 0.9)	53,395 (11.7, 1.7)
STAD	438 (65.7, 10.8)	18,809 (66.2, 14.3)	285 (64.3)	11,540 (61.4)	59 (14.2)	3631 (22.2)	130 (31.3)	2552 (15.6)	183 (44.0)	3624 (22.2)	44 (10.6)	6536 (40.0)	340 (10.8, 2.4)	16,226 (8.4, 4.5)
TGCT	134 (32.0, 9.3)	8966 (34.4, 11.8)	—	—	101 (79.5)	6145 (72.2)	12 (9.5)	1170 (13.7)	14 (11.0)	1201 (14.1)	—	—	122 (11.9, 1.0)	8170 (11.9, 1.1)
THCA	507 (47.3, 15.8)	43,969 (49.1, 15.3)	136 (26.8)	10,040 (22.8)	285 (56.4)	30,698 (72.1)	52 (10.3)	3162 (7.4)	113 (22.4)	5387 (12.7)	55 (10.9)	3333 (7.8)	412 (12.0, 0.4)	41,825 (11.8, 1.2)
THYM	123 (58.2, 13.0)	584 (58.2, 14.1)	64 (51.6)	268 (45.9)	—	—	—	—	—	—	—	—	121 (11.9, 0.7)	575 (11.5, 1.9)
UCEC	545 (63.9, 11.1)	36,753 (61.5, 11.8)	—	—	342 (62.4)	27,851 (78.8)	52 (9.5)	1657 (4.7)	124 (22.6)	3795 (10.7)	30 (5.5)	2048 (5.8)	514 (11.8, 1.1)	35,073 (11.6, 1.7)
UCS	57 (69.7, 9.3)	164 (65.4, 11.1)	—	—	22 (38.6)	20 (13.3)	5 (8.8)	11 (7.3)	20 (35.1)	47 (31.3)	10 (17.5)	72 (48.0)	55 (10.8, 2.8)	138 (9.1, 4.4)
UVM	80 (61.7, 13.9)	1315 (60.2, 14.7)	45 (56.3)	681 (51.8)	0	308 (33.2)	39 (49.4)	463 (50.0)	36 (45.6)	134 (14.5)	4 (5.1)	22 (2.4)	54 (11.6, 1.7)	911 (11.8, 1.1)

ACC adrenocortical carcinoma, BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL cholangiocarcinoma, COAD colon adenocarcinoma, DLBC lymphoid neoplasm diffuse large B-cell lymphoma, ESCA oesophageal carcinoma, GBM glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, KICH kidney chromophobe, KIPK kidney renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma, LAML acute myeloid leukaemia, LGG brain lower grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, MESO mesothelioma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PCPG pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, READ rectum adenocarcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumours, THCA thyroid carcinoma, THYM thymoma, UCEC uterine corpus endometrial carcinoma, UCS uterine carcinosarcoma, UVM uveal melanoma, SD standard deviation. ^aAll cancer types have no missing values for age in TCGA except for BRCA (one case missing), HNSC (one case missing), KIRP (three cases missing), LIHC (one case missing), LUSC (nineteen cases missing), LUAD (nineteen cases missing), SKCM (eight cases missing), STAD (five cases missing), THYM (one case missing), and UCEC (three cases missing).

Table 2. Race distribution of TCGA and NAACCR cases

Cancer types	Total		White		Black		Other	
	TCGA N	NAACCR N	TCGA N (%)	NAACCR N (%)	TCGA N (%)	NAACCR N (%)	TCGA N (%)	NAACCR N (%)
All cancers	5899	4,834,006	4845 (82.1)	4,118,891 (85.2)	500 (8.5)	548,447 (11.3)	554 (9.4)	166,668 (3.4)
BLCA	394	335,620	327 (83.0)	310,352 (92.5)	23 (5.8)	18,912 (5.6)	44 (11.2)	6356 (1.9)
BRCA	1002	1,085,443	758 (75.7)	913,884 (84.2)	183 (18.3)	128,208 (11.8)	61 (6.1)	43,351 (4.0)
CESC	271	59,092	221 (81.6)	46,030 (77.9)	30 (11.1)	9902 (16.8)	20 (7.4)	3160 (5.4)
COAD	285	477,271	215 (75.4)	397,760 (83.3)	59 (50.6)	62,360 (13.1)	11 (3.9)	17,151 (3.6)
ESCA	165	78,445	114 (69.1)	68,590 (87.4)	5 (3.0)	8034 (10.2)	46 (27.9)	1821 (2.3)
HNSC	513	416,929	454 (88.5)	364,624 (87.5)	48 (9.4)	40,315 (9.7)	11 (2.1)	11,990 (2.9)
LAML	198	65,266	181 (91.4)	56,612 (86.7)	15 (7.6)	5983 (9.2)	2 (1.0)	2671 (4.1)
LIHC	367	131,074	189 (51.5)	100,398 (76.6)	17 (4.6)	19,865 (15.2)	161 (43.9)	10,811 (8.3)
MESO	87	15,705	85 (97.7)	14,745 (93.9)	1 (1.2)	740 (4.7)	1 (1.2)	220 (1.4)
OV	556	102,308	502 (90.3)	88,406 (86.4)	34 (6.1)	9521 (9.3)	20 (3.6)	4381 (4.3)
PAAD	180	205,375	162 (90.0)	172,558 (84.0)	7 (3.9)	25,856 (12.6)	11 (6.1)	6961 (3.4)
PRAD	156	944,300	147 (94.2)	768,438 (81.4)	7 (4.5)	153,082 (16.2)	2 (1.3)	22,780 (2.4)
READ	89	188,774	82 (92.1)	157,903 (83.7)	6 (6.7)	21,534 (11.4)	1 (1.1)	9337 (5.0)
SARC	252	51,566	228 (90.5)	43,208 (83.8)	18 (7.1)	6336 (12.3)	6 (2.4)	2022 (3.9)
SKCM	460	314,232	447 (97.2)	311,095 (99.0)	1 (0.2)	1747 (0.6)	12 (2.6)	1390 (0.4)
STAD	381	108,778	279 (73.2)	83,030 (76.3)	13 (3.4)	17,535 (16.1)	89 (23.4)	8213 (7.6)
TGCT	129	38,765	119 (92.3)	36,311 (93.7)	6 (4.7)	1380 (3.6)	4 (3.1)	1074 (2.8)
THCA	414	215,063	335 (80.9)	184,947 (86.0)	27 (6.5)	17,137 (8.0)	52 (12.6)	12,979 (6.0)

BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD colon adenocarcinoma, ESCA oesophageal carcinoma, HNSC head and neck squamous cell carcinoma, LAML acute myeloid leukaemia, LIHC liver hepatocellular carcinoma, MESO mesothelioma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PRAD prostate adenocarcinoma, READ rectum adenocarcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumours, THCA thyroid carcinoma. Note: 18 cancer types were included




Fig. 1 Age at diagnosis difference between TCGA and SEER cases. Filled diamonds indicate a statistically significant difference ($P < 0.05$). The y-axis shows the effect size in terms of Cohen's d. Cohen's d was calculated as the difference between the mean diagnosis age for TCGA and SEER cases divided by the pooled standard deviation²⁴ of each cancer with Cohen's d $> |\pm 0.3|$ indicating at least a moderate effect size. Cohen's d < 0 indicates TCGA cases with a younger mean age than SEER cases

younger), and UCS (4.3 ± 1.5 years older) cases where the absolute effect size for the diagnosis age difference (Cohen's d) was ≥ 0.3 (Table 3).

Sex

For most cancer types (22/27), the observed sex distribution for TCGA cases was similar to SEER cases. Lung squamous cell carcinoma (LUSC), skin cutaneous melanoma (SKCM), and thyroid carcinoma (THCA) had a significantly higher proportion of male

cases (74.0% vs. 62.4%, 61.7% vs. 56.6%, and 26.8% vs. 22.8%, respectively), while LIHC and SARC cases had an excess of female cases (32.4% vs. 22.6%, 54.4% vs. 46.7%) in TCGA vs. SEER (Tables 1 and 3).

Race

Overall, compared to the NAACCR cases, individuals whose reported race was Other (Asian, American Indian, or Alaska Native) were over-represented in TCGA. The observed race distribution

Table 3. Differences of demographic and clinical characteristics distribution among TCGA, SEER, and NAACCR cases^a

Cancer types	Age		Sex <i>p</i> ^c	Race			<i>p</i> ^c	Stage				<i>p</i> ^c	Survival months Difference in mean survival (95% CI)
	Cohen's <i>d</i>	<i>p</i> ^b		White ^d	Black ^d	Other ^d		I ^d	II ^d	III ^d	IV ^d		
ACC	-0.27	0.009	0.63	—	—	—	—	2.04	3.27	1.6	-5.24	<0.001	1.46 (0.87, 2.06) ^e
BLCA	-0.17	<0.001	0.25	-7.12	0.17	13.46	<0.001	-20.63	2.85	19.13	10.57	<0.001	1.54 (1.29, 1.80) ^e
BRCA	-0.17	<0.001	0.15	-7.41	6.32	3.38	<0.001	-21.17	17.27	11.54	-5.48	<0.001	0.11 (0.08, 0.15) ^e
CESC	-0.12	0.04	—	1.5	-2.45	1.48	0.02	1.84	4.76	-2.99	-3.74	<0.001	0.11 (-0.07, 0.30) ^f
CHOL	-0.28	0.07	0.47	—	—	—	—	4.65	1.37	0.13	-4.71	<0.001	2.35 (1.32, 3.39) ^e
COAD	0.02	0.73	0.13	-3.58	3.82	0.24	0.001	-3.11	5.79	0.83	-3.95	<0.001	0.73 (0.51, 0.96) ^e
DLBC	-0.5	<0.001	0.21	—	—	—	—	0.3	2.67	-1.4	-1.38	0.04	1.37 (0.95, 1.78) ^e
ESCA	-0.33	<0.001	0.06	-7.09	-3.05	21.54	<0.001	-2.35	10.24	1.94	-8.13	<0.001	0.89 (0.44, 1.35) ^e
GBM	-0.29	<0.001	0.05	—	—	—	—	—	—	—	—	—	0.90 (0.58, 1.22) ^g
HNSC	-0.13	0.003	0.17	0.71	-0.24	-0.99	0.59	-8.37	2.82	0.57	4.69	<0.001	0.42 (0.19, 0.64) ^e
KICH	-0.53	<0.001	0.96	—	—	—	—	-3.85	3.01	0.71	2.78	<0.001	0.07 (-0.17, 0.31) ^e
KIRC	0.02	0.57	0.24	—	—	—	—	-5.82	1.58	3.91	2.79	<0.001	0.09 (-0.10, 0.27) ^e
KIRP	0.01	0.84	0.74	—	—	—	—	-2.62	-1.13	4.98	-0.19	<0.001	0.36 (0.24, 0.49) ^e
LAML	-0.24	<0.001	0.95	1.94	-0.77	-2.19	0.06	—	—	—	—	—	1.86 (1.34, 2.39) ^g
LGG	0.41	<0.001	0.72	—	—	—	—	—	—	—	—	—	0.52 (0.30, 0.74) ^g
LIHC	-0.33	<0.001	<0.001	-11.33	-5.61	24.64	<0.001	3.5	2.15	2.71	-9	<0.001	1.77 (1.43, 2.11) ^e
LUAD	-0.18	<0.001	0.6	—	—	—	—	16.86	14.17	0.47	-22.11	<0.001	0.48 (0.28, 0.69) ^e
LUSC	-0.24	<0.001	<0.001	—	—	—	—	15.67	13.07	-6.1	-16.56	<0.001	0.66 (0.37, 0.95) ^e
MESO	-0.69	<0.001	0.18	1.48	-1.57	-0.2	0.29	-2.27	2.15	6.09	-4.77	<0.001	1.60 (0.86, 2.34) ^e
OV	-0.24	<0.001	—	2.67	-2.59	-0.8	0.02	-6.61	-2.31	11.37	-7.13	<0.001	0.09 (-0.14, 0.31) ^f
PAAD	-0.19	0.01	0.33	2.19	-3.52	2.02	<0.001	1.06	16.22	-3.41	-13.34	<0.001	1.13 (0.66, 1.61) ^e
PCPG	-0.17	0.12	0.13	—	—	—	—	—	—	—	—	—	0.54 (0.14, 0.95) ^g
PRAD	-0.52	<0.001	—	4.12	-3.97	0.92	<0.001	—	—	—	—	—	0.05 (0.03, 0.07) ^h
READ	0.22	0.002	0.25	2.17	-1.39	-1.67	0.08	-3.3	3.33	1.15	-0.85	0.001	0.76 (0.56, 0.95) ^e
SARC	0.08	0.12	0.02	2.88	-2.48	-1.26	0.02	—	—	—	—	—	2.47 (2.19, 2.74) ^g
SKCM	-0.1	0.03	0.03	-3.69	-1.04	6.68	<0.001	-26.25	12.85	24.84	1.6	<0.001	0.37 (0.24, 0.51) ^e
STAD	-0.04	0.31	0.2	-1.42	-6.74	11.62	<0.001	-3.91	8.59	10.49	-12.13	<0.001	0.89 (0.62, 1.15) ^e
TGCT	-0.21	0.003	—	0.66	0.67	0.23	0.78	1.84	-1.4	-0.99	—	0.18	0.0003 (-0.18, 0.18) ^f
THCA	-0.12	0.008	0.03	-2.97	-1.09	5.57	<0.001	-7.78	2.44	6.51	2.54	<0.001	0.15 (0.09, 0.21) ^e
THYM	-0.01	0.95	0.25	—	—	—	—	—	—	—	—	—	0.35 (0.14, 0.57) ^g
UCEC	0.21	<0.001	—	—	—	—	—	-9.27	5.24	8.86	-0.32	<0.001	0.29 (0.18, 0.40) ^f
UCS	0.4	0.005	—	—	—	—	—	4.04	0.35	0.52	-4	<0.001	1.04 (0.04, 2.04) ^f
UVM	0.1	0.4	0.44	—	—	—	—	-6.15	-0.1	7.08	1.45	<0.001	-0.01 (-0.40, 0.37) ^e

ACC adrenocortical carcinoma, BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL cholangiocarcinoma, COAD colon adenocarcinoma, DLBC lymphoid neoplasm diffuse large B-cell lymphoma, ESCA oesophageal carcinoma, GBM glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, KICH kidney chromophobe, KIRC kidney renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma, LAML acute myeloid leukaemia, LGG brain lower grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, MESO mesothelioma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PCPG pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, READ rectum adenocarcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumours, THCA thyroid carcinoma, THYM thymoma, UCEC uterine corpus endometrial carcinoma, UCS uterine carcinosarcoma, UVM uveal melanoma. ^a*P*-values < 0.05, its corresponding effect size and 95% confidence intervals, and adjusted residuals that exceed |± 2| are bolded. ^b*P*-value was calculated using Student's *t*-test. ^c*P*-value of comparisons between TCGA and SEER (sex, stage at diagnosis) or NAACCR (race) cases was using the Chi-square test. For CHOL, KICH, UCS, and UVM, Fisher's exact test was used for the comparison of stage at diagnosis. ^dAdjusted residuals. ^eGeneralised linear models adjusted for age at diagnosis, sex, race, and stage at diagnosis. ^fGeneralised linear models adjusted for age at diagnosis, race, and stage at diagnosis. ^gGeneralised linear models adjusted for age at diagnosis, sex, and race. ^hGeneralised linear models adjusted for age at diagnosis and race

was disproportional for 13/18 cancer types (Fig. 2a). Among the 13 cancers, eight (bladder urothelial carcinoma (BLCA), BRCA, ESCA, LIHC, pancreatic adenocarcinoma (PAAD), SKCM, STAD, and THCA) had a significantly higher percentage (adjusted residuals ≥ 2) of individuals with reported Other race (Asian, American Indian, or Alaska Native) and eight (cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), ESCA, LIHC, OV, PAAD, PRAD, SARC, and STAD) had a lower percentage (adjusted

residuals ≤ -2) of reported Black race in TCGA vs. NAACCR (Table 3).

Stage at diagnosis

For the 26 TCGA cancer types with stage information, evidence for stage dissimilarities was observed for most cancer types (25/26) (Fig. 2b). Specifically, compared to SEER cases, 16 cancers had a significantly lower proportion of stage I in the TCGA cohort, 19




Fig. 2 Race and stage proportion difference. **a** Race proportion of TCGA and NAACCR cases. **b** Stage proportion of TCGA and SEER cases. The stars indicate the difference was statistically significant at an alpha threshold $P < 0.05$




Fig. 3 Survival months difference between TCGA and SEER cases. Mean survival months difference at 12-months of follow-up with corresponding 95% CIs. Dots indicate the mean survival months difference and lines represent its 95% CIs. The y-axis below zero indicates TCGA cases with a shorter survival time than SEER cases

cancers had a significantly higher proportion of stage II, 12 cancers had a significantly higher proportion of stage III, and 14 cancers had a significantly lower proportion of stage IV (Table 3).

Survival months

Using 12 months as an end point, the adjusted mean all-cause survival months were significantly longer for cases with 27/33 cancer types in TCGA relative to SEER. For the remaining six cancer types (CESC, KICH, KIRC, OV, testicular germ cell tumours (TGCT), and UVM), no statistically significant difference was found (Fig. 3). It is noteworthy that for CHOL and SARC, TCGA cases lived an average of over 2 months (2.35 and 2.47 months, respectively) longer than SEER cases after 12 months of follow-up (Table 3).

DISCUSSION

In this study, we observed that despite an approximately equal sex distribution for most cancer types included in TCGA vs. SEER data, differences exist in mean diagnosis age, race, stage at diagnosis distributions, and mean survival months. Generally, our analysis indicates that TCGA cases are younger and survive longer than those from SEER.

A previous study comparing the characteristics of TCGA cases to the U.S. general population was conducted by Spratt et al.¹⁵ The authors reported that TCGA cases with 10 cancer types compared to the U.S. population were 77% vs. 64% White, 12% vs. 12% Black, 3% vs. 5% Asian, 3% vs. 16% Hispanic, and 0.5% vs. 1–2% Native Hawaiian, Pacific Islander, Alaskan Native, or American Indian descent. White cases were over-represented and Asian and Hispanic cases were under-represented compared to the general population. However, the Spratt et al. study used the general U.S. population as the comparator, which is different from the composition of U.S. cancer patients who are one of the prime beneficiaries of TCGA results.

Another more recent study compared the distribution of TCGA cases by age to SEER cases for nine cancer types.¹⁶ Similar to our study, the age distributions for cases in the SEER database were skewed older than those in the TCGA data for nearly all cancer types examined. Specifically, TCGA cases < 70 years were well represented across most tumour types, but cases aged 80–99 years were under-represented for all cancers. These data are also consistent with that from clinical trials.³⁰ TCGA specimens are primarily from U.S. academic institutions,^{3,15} suggesting that younger patients are more likely to be seen at academic centres and participate in research where the samples were acquired. A systematic review on the recruitment of older cancer patients to clinical trials reported that age is a significant barrier to recruitment.³¹ For example, Kemeny et al. found that 68% of younger stage II breast cancer patients were offered a trial vs. 34% of the older patients ($P < 0.001$).³² It is presumed that older patients may need extra time and resources to access available clinical trials or they are often excluded because they do not meet eligibility criteria.³¹ Our results emphasize the importance of increasing access of older cancer patients to cancer genomic projects to increase the applicability of the findings to these patients.

Racial disparities in cancer incidence and survival have been well documented among various cancers. Although socioeconomic and cultural differences that differ between racial groups can explain some of the disparities, recent progress in cancer genomic sequencing allows for a molecular understanding.^{33,34} Genomic landscape differences that co-vary by race, a marker of ancestry, may influence cancer treatment. For example, one study reported that even after adjusting for smoking status and sex, race was still significantly associated with *EGFR* mutations.³⁵ *EGFR* mutations were highly prevalent in Asians at 30% vs. 7% in Whites.³⁶ In addition, results from a meta-analysis of randomised

controlled trials have reported that compared with Caucasians, Asians have a higher survival and response rate to chemotherapy.³⁷ In our study, the race distribution was notably dissimilar for 13/18 cancers, with 8/13 cancers having under-representation in individuals with Black race, which may translate to a distinct genomic landscape that may be under-represented for many cancer types. Notably, 8 of these 13 cancers had higher representation by individuals with Other race (Asian, American Indian, or Alaska Native). This over-representation may be due to TCGA cancers with small sample sizes where a relatively large proportion can be found even only with few cases in the Other population.

Stage is a well-established predictor of cancer prognosis and survival.³⁸ Studies have also reported notable genetic variation in cancers by stage.^{39,40} In our study, stage dissimilarities existed for almost all cancer types (25/26). However, these identified differences between datasets may be due to the fact that only individuals who had a resection procedure were included in TCGA.¹⁴ Individuals with unresectable cancers, such as cancers with advanced stage or metastatic cancer,⁴¹ did not meet the inclusion criteria of the program, which likely led to a lower stage distribution of the cases in TCGA compared to SEER. In addition, other differences may have contributed to stage differences including the sample eligibility requirements of only untreated first primary tumour samples being fresh frozen.¹⁴

To our knowledge, this is the largest study to compare clinical characteristics of TCGA cancer cases to a sample of the general population of U.S. cancer cases. However, our study has limitations. No specific diagnosis criteria for each cancer type have been published for TCGA to our knowledge. Thus, the corresponding cancers in SEER were matched by cancer site and histology, and identified by ICD-O-3 primary site and histology/behavior code. Moreover, cases with certain cancers had missing race, stage, and survival months information. Particularly, 6/33 TCGA cancer types (THCA, LUSC, PRAD, COAD, READ, and UVM) had over 15% missing data on race, and 5/26 SEER cancers (BLCA, LIHC, MESO, CHOL, and UVM) had over 15% missing data on stage. In addition, for the race comparison, only 18 cancers in NAACCR were identified with sites matching to those of TCGA cases.

In conclusion, we found dissimilarities in the distributions of demographic and clinical characteristics between TCGA and general population cancer cases for the majority of cancers. Increased awareness of under-represented groups by researchers conducting cancer genomic research will allow for targeted efforts that increase the representativeness of genomic data that is important for precision medicine.

AUTHOR CONTRIBUTIONS

X.W. analysed data, wrote, and revised the paper. J.S. contributed to the method section and revisions on the manuscript. M.H.B. revised the figures and the manuscript. Q.F. and H.P. replicated the results to ensure reproducibility of findings. K.J. supervised the project.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at <https://doi.org/10.1038/s41416-018-0140-8>.

Competing interests: The authors declare no competing interests.

Availability of data and materials: TCGA: <https://portal.gdc.cancer.gov/> SEER: www.seer.cancer.gov NAACCR: <https://faststats.naacr.org/>

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

REFERENCES

1. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* **505**, 495–501 (2014).
2. Saha, S. K. et al. Corrigendum: mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer. *Nature* **528**, 152 (2015).
3. Tomczak, K., Czerwinski, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. *Contemp. Oncol.* **19**, A68–A77 (2015).
4. National Institute of Health, National Cancer Institute, National Human Genome Research Institute. TCGA program overview. <http://cancergenome.nih.gov/abouttcga/overview> (2016).
5. Calvo, E. & Baselga, J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. *J. Clin. Oncol.* **24**, 2158–2163 (2006).
6. Shi, Y. et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). *J. Thorac. Oncol.* **9**, 154–162 (2014).
7. Kurian, A. W. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. *Curr. Opin. Obstet. Gynecol.* **22**, 72–78 (2010).
8. Cote, M. L. et al. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers. *Int. J. Gynecol. Cancer* **22**, 1367–1372 (2012).
9. Keenan, T. et al. Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumour recurrence. *J. Clin. Oncol.* **33**, 3621–3627 (2015).
10. Tan, D. S., Mok, T. S. & Rebbeck, T. R. Cancer genomics: diversity and disparity across ethnicity and geography. *J. Clin. Oncol.* **34**, 91–101 (2016).
11. Dresler, C. M. et al. Gender differences in genetic susceptibility for lung cancer. *Lung Cancer* **30**, 153–160 (2000).
12. Hwang, S. J., Lozano, G., Amos, C. I. & Strong, L. C. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. *Am. J. Hum. Genet.* **72**, 975–983 (2003).
13. Liu, L., Zhang, J., Wu, A. H., Pike, M. C. & Deapen, D. Invasive breast cancer incidence trends by detailed race/ethnicity and age. *Int. J. Cancer* **130**, 395–404 (2012).
14. National Institute of Health, National Cancer Institute, National Human Genome Research Institute. TCGA tissue sample requirements: high quality requirements yield high quality data. <https://cancergenome.nih.gov/cancersselected/biospeccriteria> (2018).
15. Spratt, D. E. et al. Racial/ethnic disparities in genomic sequencing. *JAMA Oncol.* **2**, 1070–1074 (2016).
16. Wahl, D. R. et al. Pan-cancer analysis of genomic sequencing among the elderly. *Int. J. Radiat. Oncol. Biol. Phys.* **98**, 726–732 (2017).
17. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2017 Sub (1973-2015) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.
18. Weir, H. K. et al. Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies. *J. Natl Cancer Inst. Monogr.* **2014**, 198–209 (2014).
19. National Institute of Health, National Cancer Institute. NCI genomic data commons data portal. <https://portal.gdc.cancer.gov/> (2016).
20. North American Association of Central Cancer Registries. NAACCR fast stats: an interactive tool for quick access to key NAACCR cancer statistics. <http://www.naacr.org/> (2016).
21. Surveillance Epidemiology and End Results (SEER) Program. About the SEER registries. <https://seer.cancer.gov/registries/> (2016).
22. North American Association of Central Cancer Registries. Cancer in North America CINA volumes. <https://www.naacr.org/cancer-in-north-america-cina-volumes/> (2016).
23. Surveillance Epidemiology and End Results (SEER) Program. Survival time calculation. <https://seer.cancer.gov/survivaltime/SurvivalTimeCalculation.pdf> (2016).
24. Fritz, C. O., Morris, P. E. & Richler, J. J. Effect size estimates: current use, calculations, and interpretation. *J. Exp. Psychol. Gen.* **141**, 2–18 (2012).
25. Royston, P. & Parmar, M. K. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. *BMC Med. Res. Methodol.* **13**, 152 (2013).
26. Zhao, L. et al. On the restricted mean survival time curve in survival analysis. *Biometrics* **72**, 215–221 (2016).
27. A'Hern, R. P. Restricted mean survival time: an obligatory end point for time-to-event analysis in cancer trials? *J. Clin. Oncol.* **34**, 3474–3476 (2016).
28. Andersen, P. K. & Perme, M. P. Pseudo-observations in survival analysis. *Stat. Methods Med. Res.* **19**, 71–99 (2010).
29. Andersen, P. K., Hansen, M. G. & Klein, J. P. Regression analysis of restricted mean survival time based on pseudo-observations. *Lifetime Data Anal.* **10**, 335–350 (2004).
30. Murthy, V. H., Krumholz, H. M. & Gross, C. P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. *J. Am. Med. Assoc.* **291**, 2720–2726 (2004).
31. Townsley, C. A., Selby, R. & Siu, L. L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. *J. Clin. Oncol.* **23**, 3112–3124 (2005).
32. Kemeny, M. M. et al. Barriers to clinical trial participation by older women with breast cancer. *J. Clin. Oncol.* **21**, 2268–2275 (2003).
33. Burchard, E. G. et al. The importance of race and ethnic background in biomedical research and clinical practice. *N. Engl. J. Med.* **348**, 1170–1175 (2003).
34. El-Telbany, A. & Ma, P. C. Cancer genes in lung cancer: racial disparities: are there any? *Genes Cancer* **3**, 467–480 (2012).
35. Bauml, J. et al. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? *Lung Cancer* **81**, 347–353 (2013).
36. Zhou, W. & Christiani, D. C. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. *Chin. J. Cancer* **30**, 287–292 (2011).
37. Soo, R. A. et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. *J. Thorac. Oncol.* **6**, 1030–1038 (2011).
38. Naruke, T., Goya, T., Tsuchiya, R. & Suemasu, K. Prognosis and survival in resected lung carcinoma based on the new international staging system. *J. Thorac. Cardiovasc. Surg.* **96**, 440–447 (1988).
39. Blaveri, E. et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. *Clin. Cancer Res.* **11**, 7012–7022 (2005).
40. Richter, J. et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. *Cancer Res.* **57**, 2860–2864 (1997).
41. Balaban, E. P. et al. Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline. *J. Clin. Oncol.* **34**, 2654–2668 (2016).